Every 10-Q that 908 Devices Inc. (MASS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MASS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MASS filings page.
908 Devices Inc. develops handheld and program devices for chemical analysis serving defense, public safety and industrial customers. For the six months ended June 30, 2026, revenue from continuing operations was $29.5 million, up from $24.8 million, driven mainly by handheld product sales. Q2 revenue was $16.1 million.
The company reported a continuing-operations net loss of $23.8 million for the first half of 2026 and an accumulated deficit of $247.2 million. Results were pressured by operating expenses of $40.9 million, including a $12.8 million non-cash increase in contingent consideration tied to recent acquisitions.
Liquidity remains solid with $63.0 million of cash and $38.5 million of marketable securities and positive operating cash flow of $4.4 million in the first half. The company closed the NIRLAB acquisition, expanding narcotics-detection capabilities, and continues to recognize the effects of its 2025 Desktop Portfolio divestiture and related transition services. A new $20 million undrawn revolving credit facility extends financial flexibility.
908 Devices reported Q1 2026 revenue from continuing operations of $13.4 million, up from $11.8 million a year earlier, driven mainly by higher handheld device sales. Recurring revenue, including consumables, accessories and services, represented 30% of total revenue.
The company posted a net loss from continuing operations of $12.0 million (or $0.32 per share), compared with a loss of $9.8 million in Q1 2025, which had been offset at the time by a large gain from the prior-year sale of its Desktop Portfolio.
As of March 31, 2026, 908 Devices held $67.6 million in cash and cash equivalents and $44.2 million in marketable securities, and believes these resources plus revenue will fund operations for at least 12 months. Deferred revenue totaled $18.5 million, reflecting future product and service obligations, and a $20 million undrawn revolving credit facility was put in place in March 2026.
The RedWave acquisition performance targets were achieved, increasing contingent consideration to $22.4 million. After quarter-end, the company agreed to acquire Switzerland-based NIRLAB for headline consideration of $15.0 million in cash and stock to expand its material identification capabilities.
908 Devices Inc. (MASS) reported Q3 2025 results. Revenue was $14.0 million, slightly below $14.5 million a year ago, while year-to-date revenue rose to $38.8 million from $33.4 million. Gross profit for the quarter was $7.4 million.
Operating expenses reflected a $10.7 million increase in the fair value of contingent consideration, driving a Q3 loss from continuing operations of $14.9 million. Year-to-date loss from continuing operations was $37.7 million.
The company completed the sale of its Desktop Portfolio to Repligen, recording a $56.1 million gain within discontinued operations. As a result, year-to-date net income attributable to common stockholders was $15.3 million.
Liquidity strengthened with cash and cash equivalents of $62.8 million and marketable securities of $49.3 million at September 30, 2025. Deferred revenue was $18.3 million. A current contingent consideration liability of $23.0 million reflects updated fair value tied to prior acquisitions.
Shares outstanding were 36,118,576 at September 30, 2025; as of November 5, 2025, they were 36,192,978.
Q2-25 continuing ops showed top-line growth but remained unprofitable. Revenue rose 14% YoY to $13.0 M, driven by handheld device sales (+13%) and recurring revenue (+28%). Gross profit improved 3% to $6.4 M, yet margin contracted to 48.9% (53.8% LY) as product cost inflation outpaced pricing. Operating expenses climbed 47% to $21.5 M, largely from a $6.8 M fair-value increase in RedWave acquisition earn-out; R&D grew 23% and SG&A eased 7%. As a result, loss from continuing ops widened to $12.9 M (-$7.6 M LY), or –$0.36 per share.
Strategic divestiture transformed the six-month picture. On 4 Mar 25, MASS sold its Desktop Portfolio to Repligen for $69.9 M cash, booking a $56.2 M pre-tax gain. Including this, H1-25 net income reached $30.3 M versus a $23.5 M loss LY; EPS swung to +$0.85. Cash & equivalents jumped to $61.8 M (43.4 M YE-24) and marketable securities to $56.8 M, lifting current assets to $147.9 M. Total liabilities fell slightly to $42.9 M, though a new $11.6 M current liability reflects contingent consideration. Operating cash burn for H1 was $20.8 M, covered by divestiture proceeds; capex remained modest at $0.3 M. Shares outstanding were 36.06 M at 30 Jun 25. A June-25 master supply agreement secures $6.6 M in committed orders over three years, with a $0.75 M upfront payment received in July.